Hims & Hers Health rises after narrowing 2025 EBITDA guidance, Q3 EPS miss

6 hours ago 1

Comments

Third Quarter Q3 Profits Stock Trading Chart 3D Background

Hims & Hers Health (HIMS) is up ~7% in after-hours trading Monday after narrowing its full-year adjusted EBITDA outlook range.

The telehealth company now sees 2025 adjusted EBITDA of $307M-$317M, from $295-$335M prior.

Hims & Hers also narrowed its revenue guidance range

Recommended For You

More Trending News

Read Entire Article